JPWO2023164143A5 - - Google Patents
Info
- Publication number
- JPWO2023164143A5 JPWO2023164143A5 JP2024550167A JP2024550167A JPWO2023164143A5 JP WO2023164143 A5 JPWO2023164143 A5 JP WO2023164143A5 JP 2024550167 A JP2024550167 A JP 2024550167A JP 2024550167 A JP2024550167 A JP 2024550167A JP WO2023164143 A5 JPWO2023164143 A5 JP WO2023164143A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- subject
- fraction
- dosing regimen
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313932P | 2022-02-25 | 2022-02-25 | |
| US63/313,932 | 2022-02-25 | ||
| US202263393212P | 2022-07-28 | 2022-07-28 | |
| US63/393,212 | 2022-07-28 | ||
| US202263420782P | 2022-10-31 | 2022-10-31 | |
| US63/420,782 | 2022-10-31 | ||
| US202263424210P | 2022-11-10 | 2022-11-10 | |
| US63/424,210 | 2022-11-10 | ||
| US202363440304P | 2023-01-20 | 2023-01-20 | |
| US63/440,304 | 2023-01-20 | ||
| PCT/US2023/013836 WO2023164143A1 (en) | 2022-02-25 | 2023-02-24 | Dosing regimens for mitigation of cytokine release syndrome with odronextamab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508832A JP2025508832A (ja) | 2025-04-10 |
| JPWO2023164143A5 true JPWO2023164143A5 (enExample) | 2026-02-27 |
Family
ID=85778997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024550167A Pending JP2025508832A (ja) | 2022-02-25 | 2023-02-24 | サイトカイン放出症候群の軽減のための投与レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230272118A1 (enExample) |
| EP (1) | EP4482524A1 (enExample) |
| JP (1) | JP2025508832A (enExample) |
| KR (1) | KR20240167457A (enExample) |
| CN (1) | CN119156226A (enExample) |
| AU (1) | AU2023224098A1 (enExample) |
| CA (1) | CA3244791A1 (enExample) |
| IL (1) | IL315011A (enExample) |
| MX (1) | MX2024010292A (enExample) |
| TW (1) | TW202400228A (enExample) |
| WO (1) | WO2023164143A1 (enExample) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| IL280875B2 (en) * | 2018-08-31 | 2024-12-01 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| TW202135860A (zh) | 2019-12-10 | 2021-10-01 | 美商再生元醫藥公司 | 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
-
2023
- 2023-02-23 TW TW112106608A patent/TW202400228A/zh unknown
- 2023-02-24 AU AU2023224098A patent/AU2023224098A1/en active Pending
- 2023-02-24 CN CN202380035668.7A patent/CN119156226A/zh active Pending
- 2023-02-24 JP JP2024550167A patent/JP2025508832A/ja active Pending
- 2023-02-24 WO PCT/US2023/013836 patent/WO2023164143A1/en not_active Ceased
- 2023-02-24 CA CA3244791A patent/CA3244791A1/en active Pending
- 2023-02-24 EP EP23713991.0A patent/EP4482524A1/en active Pending
- 2023-02-24 US US18/114,057 patent/US20230272118A1/en active Pending
- 2023-02-24 IL IL315011A patent/IL315011A/en unknown
- 2023-02-24 KR KR1020247032140A patent/KR20240167457A/ko active Pending
-
2024
- 2024-08-21 MX MX2024010292A patent/MX2024010292A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8734799B2 (en) | Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer | |
| US20200206228A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| US12194095B2 (en) | Combinations and uses thereof | |
| CN112154156A (zh) | 抗cd38抗体的皮下给药 | |
| EP2699598A2 (en) | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer | |
| JP2021501217A (ja) | 同種キメラ抗原受容体ｔ細胞投与のための方法および組成物 | |
| CN109999195A (zh) | 类风湿关节炎的治疗 | |
| KR20070104593A (ko) | 치료 방법 | |
| AU2017219596A1 (en) | Chimeric canine anti-CD20 antibody | |
| US20250074979A1 (en) | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma | |
| TW202206100A (zh) | 癌症之治療 | |
| JPWO2022076462A5 (enExample) | ||
| JPWO2023164143A5 (enExample) | ||
| TW202302642A (zh) | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 | |
| RU2024126679A (ru) | Схемы введения доз для ослабления синдрома высвобождения цитокинов при применении одронекстамаба | |
| JPWO2022098628A5 (enExample) | ||
| RU2021128133A (ru) | Введение ингибиторов pd-1 для лечения рака кожи | |
| RU2025131684A (ru) | Способы лечения множественной миеломы | |
| RU2023130537A (ru) | Введение доз для лечения биспецифическим антителом к cd20/cd3 | |
| RU2025127783A (ru) | Способы лечения рака с помощью биспецифических молекул анти-cd22 x анти-cd28 | |
| RU2025126669A (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности лечения меланомы | |
| JPWO2023177772A5 (enExample) | ||
| JPWO2020176748A5 (enExample) | ||
| JPWO2023133280A5 (enExample) | ||
| JPWO2023009498A5 (enExample) |